Skip to main content
    A

    Axsome Therapeutics Inc (AXSM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $132.37
    +2.57 (+1.98%)

    Market Cap: $7.21B

    Last updated: Nov 06, 2026 at 4:27 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    45%(18/40)
    Avg Surprise
    -6.20%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$-0.71
    Range$-1.51 - $-0.00
    13 analysts
    Revenue Consensus
    $288M
    Range$213M - $330M
    21 analysts
    Last 12 of 40 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-0.71$-1.51 - $-0.00--13--
    Sep 26
    Reported Nov 2
    		$-0.25N/A-+63.77%Beat13
    0
    3
    30d
    		+73.4%
    Jun 26
    Reported Aug 10
    		$-0.99$-0.99$-1.25 - $-0.05+0.00%Beat11
    1
    0
    30d
    		-2.1%
    Mar 26
    Reported May 4
    		$-1.26$-0.86$-1.05 - $-0.21-46.51%Miss6
    1
    2
    30d
    		-3.3%
    Dec 25
    Reported Feb 23
    		$-0.56$-0.73$-1.16 - $-0.28+22.82%Beat15
    4
    1
    30d
    		+63.6%
    Sep 25
    Reported Nov 3
    		$-0.94$-0.90$-1.19 - $-0.57-4.44%Miss14
    1
    3
    30d
    		+30.0%
    Jun 25
    Reported Aug 4
    		$-0.97$-1.09$-1.24 - $-0.75+11.01%Beat13
    0
    6
    30d
    		+41.9%
    Mar 25
    Reported May 5
    		$-1.22$-1.35$-1.69 - $-0.81+9.63%Beat10
    1
    3
    30d
    		+15.3%
    Dec 24
    Reported Feb 18
    		$-1.54$-1.00$-1.32 - $-0.55-53.60%Miss11
    6
    2
    30d
    		+26.0%
    Sep 24
    Reported Nov 12
    		$-1.34$-1.41$-1.70 - $-0.78+4.83%Beat16
    3
    0
    30d
    		-1.7%
    Jun 24
    Reported Aug 5
    		$-1.67$-1.33$-1.67 - $-0.97-25.56%Miss16
    2
    0
    30d
    		-8.4%
    Mar 24
    Reported May 6
    		$-1.44$-1.22$-1.45 - $-0.98-18.03%Miss15
    2
    1
    30d
    		-453.8%
    Dec 23
    Reported Feb 20
    		$-2.08$-1.17$-1.36 - $-1.07-77.78%Miss14
    2
    1
    30d
    		-47.5%

    Key Metrics

    Valuation
    P/E Ratio-43.26EV/EBITDAN/A
    Price/FCF-84.03xFCF Yield-1.19%
    Profitability
    Profit Margin-18.20%Operating Margin-5.18%
    ROE-175.60%ROIC-48.11%
    Financial Health
    Debt/Equity1.98xInterest CoverageN/A
    Current Ratio1.42xQuick Ratio1.34x
    Trading Statistics
    Beta0.83Avg Volume1.09M
    52-Week High$260.1952-Week Low$123.00

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$139.24
    SMA 20$148.44
    SMA 50$177.62
    SMA 200$198.14
    EMA 10$139.68
    EMA 20$148.97
    EMA 50$170.86
    EMA 200$186.97

    MACD

    Line: -12.70Signal: -12.59Hist: -0.12

    ADX

    ADX: 45.1+DI: 13.4-DI: 37.7

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down84.0
    PSAR$138.88

    Bollinger Bands

    Upper Band$170.04
    Lower Band$126.83
    %B Position2911%(Upper)
    Band Width0.13

    RSI (14-Day)

    Oversold
    25.2

    Momentum Oscillators

    Stoch %K24.1
    Stoch %D28.2
    Williams %R-77.6
    ROC (10d)-8.7%
    Momentum-12.67
    CCI (20d)-111.0
    MFI (14d)19.7

    Volatility Measures

    ATR (14d)$7.88(6.0%)
    StdDev (20d)10.80
    Hist Vol47.8%(High)

    Volume Flow

    VWAP$132.05
    OBV-1.7M
    AD Line-5.9M
    CMF (20d)-0.102

    Volume Metrics

    Avg Vol (20d)1.1M
    Vol Ratio0.7x
    VWMA (20d)$146.20

    Pivot Points

    R3$143.81
    R2$140.69
    R1$135.24
    Pivot Point$132.12
    S1$126.67
    S2$123.55
    S3$118.10

    Advanced Oscillators

    TSI-53.14
    Ultimate Osc50.0
    KST-231.74

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$259.69M$218.38M$191.20M$196.00M$170.99M$150.04M$121.46M$118.77M$104.76M$87.17M$75.00M$71.53M
    Cost of Revenue$17.80M$13.56M$14.72M$12.33M$11.91M$13.45M$9.79M$10.51M$8.44M$8.05M$6.30M$7.38M
    Gross Profit$241.89M$204.81M$176.48M$183.67M$159.08M$136.59M$111.67M$108.25M$96.33M$79.11M$68.70M$64.15M
    Operating Expenses$252.96M$254.46M$239.84M$210.63M$205.19M$173.31M$168.66M$180.87M$158.95M$157.16M$135.98M$162.43M
    R&D$50.62M$46.23M$52.68M$48.79M$40.16M$49.54M$44.78M$55.01M$45.39M$49.85M$36.83M$30.80M
    SG&A$203.11M$208.14M$185.00M$169.30M$150.24M$130.28M$120.79M$113.27M$95.56M$103.55M$98.97M$86.81M
    Operating Income$-11,068,000$-49,646,000$-63,357,000$-26,957,000$-46,109,000$-36,714,000$-56,982,000$-72,617,000$-62,624,000$-78,046,000$-67,275,000$-98,274,000
    Interest Income$-1,721,000$-1,540,000$-1,185,000$-1,172,000$-1,120,000$-1,834,000$-2,431,000$-2,210,000$-1,978,000$-1,299,000$-1,082,000$-702,000
    Interest Expense$0$0$1.19M$1.17M$0$10.38M$2.43M$2.21M$0$0$1.08M$702,000
    Income Before Tax$-12,789,000$-51,186,000$-64,542,000$-28,129,000$-47,229,000$-48,933,000$-59,413,000$-74,827,000$-64,602,000$-79,345,000$-68,357,000$-98,976,000
    Income Tax Expense$88,000$128,000$0$430,000$0$-960,000$0$85,000$0$0$0$-325,000
    Net Income$-12,877,000$-51,314,000$-64,542,000$-28,559,000$-47,229,000$-47,973,000$-59,413,000$-74,912,000$-64,602,000$-79,345,000$-68,357,000$-98,651,000
    EBITDA$-7,844,000$-46,595,000$-60,831,000$-24,522,000$-43,540,000$-34,151,000$-54,182,000$-69,836,000$-59,891,000$-75,412,000$-64,825,000$-96,080,000
    EBIT$-11,068,000$-49,646,000$-63,357,000$-26,957,000$-46,109,000$-36,714,000$-56,982,000$-72,617,000$-62,624,000$-78,046,000$-67,275,000$-98,274,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about AXSM

    News

    Axsome Therapeutics (AXSM) Stock May Be Reasonable On Strong Q3 Revenue Growth

    Axsome Therapeutics (AXSM) has seen substantial share price growth over the past five years, despite a recent pullback. With strong Q3 revenue growth and an expanding neuroscience pipeline...

    Simply Wall St•11/6/26•Somewhat-Bullish

    UBS Adjusts Axsome Therapeutics Price Target to $239 From $256, Maintains Buy Rating

    UBS has adjusted its price target for Axsome Therapeutics (AXSM) shares to $239 from $256, while reiterating a Buy rating on the stock. This revision follows recent updates regarding AXSM's Auvelity prescription trends...

    Moomoo•11/3/26•Somewhat-Bullish

    UBS maintains Axsome Therapeutics at Buy, lowers price target to $239 from $256

    UBS maintained its "Buy" rating for Axsome Therapeutics (AXSM) but lowered its price target to $239 from $256, representing a 6.6% decrease. This new price target implies a potential upside of 75.7% from the stock's...

    TradingView•11/3/26•Somewhat-Bullish

    Axsome Therapeutics reports Q3 EPS (25c), consensus (56c)

    Axsome Therapeutics reported Q3 EPS of (25c), significantly beating the consensus of (56c), and revenue of $259.69M, surpassing the $249.93M consensus. The company achieved 52% year-over-year total revenue growth...

    TipRanks•11/2/26•Neutral

    Axsome Therapeutics 3Q 2026: Revenue $259.7M, Net loss $12.9M, EPS $(0.25) — 10-Q Summary

    Axsome Therapeutics reported its third-quarter 2026 results, showing a significant increase in revenue to $259.7 million, up 51.9% year-over-year. The company's net loss narrowed to $12.9 million...

    TradingView•11/2/26•Somewhat-Bullish

    AXSM Valuation and Fair Value

    P/E
    -43.3x
    Forward P/E
    26.1x
    P/FCF
    -84.0x
    PEG
    0.0x
    P/B
    65.8x
    See GNG's fair value

    AXSM Profitability: Margins, ROIC and FCF

    Gross margin
    93.2%
    Operating margin
    -5.2%
    Net margin
    -18.2%
    ROIC
    -48.1%
    ROE
    -175.6%
    FCF margin
    -9.5%
    FCF yield
    -1.2%

    AXSM Competitors

    CompanyTicker
    Praxis Precision Medicines IncPRAX
    Kiniksa Pharmaceuticals LtdKNSA
    Caris Life Sciences, Inc. Common StockCAI
    Merus BVMRUS
    Abivax SA American Depositary SharesABVX
    Amneal Pharmaceuticals, Inc. Class A Common StockAMRX
    10X Genomics IncTXG
    Ionis Pharmaceuticals IncIONS

    Sector: Healthcare

    AXSM Analyst Ratings

    Consensus
    Buy
    Analysts
    22
    Strong Buy
    3
    Buy
    18
    Hold
    1
    Sell
    0
    Strong Sell
    0

    AXSM Bull Case vs Bear Case

    Bull case

    • AXSM grew quarterly revenue 51.9% year over year.
    • 95.5% of AXSM's analyst ratings are Buy or Strong Buy.

    Bear case

    • AXSM has a -18.2% net profit margin.

    AXSM Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    0.3%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $-0.71

    AXSM Earnings Date

    AXSM reports Feb 10, 2027, after the close. The date is estimated.

    AXSM Earnings Call

    The latest AXSM earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    AXSM ETF Holders

    GNG tracks 16 ETFs that hold AXSM. The largest weights:

    1. State Street SPDR S&P Pharmaceuticals ETF (XPH), 1.37% of the fund
    2. abrdn Healthcare Investors (HQH), 1.13% of the fund
    3. iShares Biotechnology ETF (IBB), 0.44% of the fund
    4. Royce Value Trust Inc (RVT), 0.31% of the fund
    5. Vanguard Morningstar Small-Cap Growth ETF (VBK), 0.23% of the fund
    Open the ETF Stock Exposure tool for AXSM

    See insider activity

    Frequently Asked Questions About AXSM

    When does AXSM report earnings?

    Axsome Therapeutics Inc (AXSM) is expected to report earnings on Feb 10, 2027.

    Does AXSM pay dividends?

    Axsome Therapeutics Inc (AXSM) does not currently pay a regular dividend.

    What is AXSM's market cap?

    Axsome Therapeutics Inc (AXSM) has a market capitalization of $7.21B with a current stock price of $132.37.

    Related stocks

    Sector: Healthcare

    All stocks starting with A

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In